| Description |
1 online resource |
| Contents |
Front Cover; Anticandidal Agents; Copyright Page; Contents; List of Figures; List of Tables; 1 Introduction; Pathogenesis and Virulence; Genome and Proteome; Genetics; Metabolome; 2 Host-Pathogen Interaction; Morphogenesis; Immune Responses; Delayed-Type Hypersensitivity; Pattern Recognition Receptors; TH Cell Response; 3 Antifungals Used Against Candidiasis; Azoles; Activity and Mechanism of Action; Azole Variants and Their Structure; Ketoconazole; Itraconazole; Fluconazole; Voriconazole; Posoconazole; Ravuconazole; Terconazole; Other Notable Triazoles Include; Polyenes |
|
Activity and Mechanism of ActionStructure and Variants; Amphotericin B; Nystatin; Natamycin; Echinocandins; Activity and Mechanism of Action; Echinocandins Variants; Caspofungin; Micafungin; Anidulafungin; Pneumocandins; Echinocandin B; Cilofungin; Allylamines; Activity and Mechanism of Action; Variants of Allylamines; Terbinafine; Naftifine; Pyrimidines; Activity and Mechanism of Action; Pyrimidine Variants; 5-FC or Flucytosine; Thiocarbamates and Morpholines; Tolnaftate; Morpholines; Other Inhibitors; Cell Wall Synthesis Inhibitors; Chitin Biosynthesis Inhibitors |
|
Ergosterol Biosynthesis InhibitorGlucan Synthesis Inhibitors; Novel Inhibitors; Expected Drugs (Compounds in Pipeline); SCY078; Ara-sertaconazole Nitrate; VT-1161; MGCD290; E1210; T-2307; ASP9726; Biafungin (CD101); Isavuconazole; Albaconazole; BQM-Bis [1, 6]quinolizinium 8-Methyl-Salt; Quinazolines; Indole and its Derivatives; Inhibitor Molecules; Sordarins; Tacrolimus; Ascomycin; Milbemycin; Unnarmicin A and Unnarmicin C; Verapamil; Disulfiram; Enniatin B; Trichostatin A; Levofloxacin and Derivatives; Differential Expression of Genes in Response to Drugs; 4 Drug Resistance in Candida |
|
Emergence of Drug ResistanceSpread of Drug Resistance; Persistence of Drug Resistance; International Data; National Data; Multidrug Resistance; 5 Multidrug Resistance and Transporters; Overview of Efflux Pumps; ABC Transporters; MFS Transporters; Fungal Efflux-Mediated Drug Resistance; Overcoming Efflux-Mediated Drug Resistance; 6 Potential Anticandidal Targets; Surface Targets; ABC Transporters; Key Factors; MFS Transporters; QDR; Cellular Targets; Cross Talk; 7 Drug Development Strategies; In Vitro Based; Biochemical Estimation; Toxicity Assay; Drug Susceptibility; Effects on Biofilm |
|
In Vivo BasedBioavailability; Toxicity; ADME; Absorption and Distribution; Metabolism and Excretion; Pharmacokinetics and Pharmacodynamics; In Silico Based; Computer-Aided Drug Discovery and Development; Molecular Docking; Molecular Modeling; Virtual Screening; Quantitative Structured Activity Relationship; 8 Conclusion; Abbreviations; Bibliography; Back Cover |
| Summary |
Anticandidal Agents provides the latest information on candida drug resistance and its remedial implications. In this compilation, users will find a comprehensive view on overcoming resistance in anticandidal drugs, along with information on novel molecules. Candida albicans is an opportunistic pathogenic fungus responsible for life threating invasive and nosocomial infections across the globe. Candidiasis is a major cause of morbidity among immunocompromised patients. Infections caused by non-albicans candida like C. glabrata, C. parapsilosis, and C. tropicalis have also imposed a serious threat in the last few decades. Current treatment of candidiasis relies primarily on antifungal agents broadly categorized as azoles, polyenes, echinocandins, allylamines, and pyrimidines. Lately, antifungal resistance has emerged to be an obstruction of current treatment regime. A number of reasons are described in detail. Understanding the mechanisms of resistance is crucial for developing strategies for overcoming the hindrance in current therapeutics. Presents a complete understanding of candida resistance to help in the development of therapeutic expansion and novel drugs Provides thorough information on candida drug resistance and its remedial implications Covers crucial mechanisms of resistance that will help develop strategies for overcoming the hindrance in current therapeutics |
| Bibliography |
Includes bibliographical references |
| Notes |
Print version record |
| Subject |
Candidiasis -- Chemotherapy
|
|
Candidiasis -- therapy
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
| Form |
Electronic book
|
| ISBN |
012811312X |
|
9780128113127 |
|
